Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. reported that Chief Technology and Manufacturing Officer Gregory Russotti received new equity awards. On February 2, 2026, he was granted 135,000 shares of common stock in the form of restricted stock units at $0 per share, increasing his directly held common stock to 525,982 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service.
Russotti was also granted a stock option for 265,000 shares of common stock at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the balance in 36 equal monthly installments thereafter. In addition, 92,773 shares of common stock are reported as indirectly owned through the Gregory Russotti 2021 Family Trust.
Century Therapeutics Chief Scientific Officer Chad Cowan received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 135,000 restricted stock units at no cash cost, increasing his directly held common stock to 1,178,476 shares. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over the following three years, subject to his continued service. He was also granted a stock option covering 265,000 shares of common stock at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the balance in 36 equal monthly installments, also subject to continued service. Separately, 10,697 shares are held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except for any pecuniary interest.
Century Therapeutics reported that Douglas Carr, its SVP Finance & Operations, received equity awards. He was granted 110,000 restricted stock units, each representing one share of common stock, vesting 25% on February 2, 2027 and the remaining 75% quarterly over three years, subject to continued service.
He was also granted a stock option for 225,000 shares at an exercise price of $1.84 per share, vesting 25% on February 2, 2027 and the remaining 75% in 36 equal monthly installments, expiring on February 2, 2036. After these grants, he beneficially owns 514,874 common shares directly and 225,000 options.
Century Therapeutics, Inc. held a special stockholder meeting where investors approved an amendment to its charter that would allow a reverse stock split of its common stock at a ratio between 1-for-5 and 1-for-30, at the discretion of the board. The proposal received 55,089,478 votes for, 5,361,020 against, and 27,055 abstentions, indicating strong support for the potential split. On the same day, the company received notice from the Nasdaq Stock Market that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. Because the company is now in compliance with all continued listing standards, it does not intend to implement the reverse stock split that stockholders approved.
Century Therapeutics, Inc. received a Schedule 13G from RA Capital Management and related parties reporting a significant passive ownership position. RA Capital Healthcare Fund directly holds 17,754,430 shares of common stock, plus pre-funded warrants exercisable for up to 8,332,526 shares and additional warrants exercisable for up to 13,043,478 shares of common stock. A beneficial ownership blocker in these warrants limits the group’s exercisability so that total beneficial ownership does not exceed 9.99% of Century’s common stock, which is currently 17,944,649 shares.
The 9.99% figure is calculated using 87,405,311 shares outstanding as of November 25, 2025, plus 92,030,595 shares issued in a January 9, 2026 private placement and 190,219 shares issuable upon warrant exercise. RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and individuals Peter Kolchinsky and Rajeev Shah report shared voting and dispositive power over these securities and certify they are not holding them to change or influence control of Century Therapeutics.
Century Therapeutics, Inc. received a Schedule 13G from a group of Venrock-affiliated investment entities and individuals reporting a significant ownership position. The group reports beneficial ownership of 13,043,478 shares of common stock (including shares underlying warrants that are immediately exercisable for 4,347,826 shares), representing 7.1% of the common stock. The holdings are spread across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., and related management entities, with Nimish Shah and Bong Koh as voting members of the managing entities. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.
Century Therapeutics, Inc. (IPSC) received a Schedule 13G filing from Commodore Capital and related parties. The filing reports beneficial ownership of 13,043,478 shares of Century Therapeutics common stock, representing 7.1% of the outstanding class.
The position consists of 8,695,652 shares of common stock plus 4,347,826 additional shares underlying a warrant. Ownership percentages are based on 179,337,686 shares outstanding as of January 9, 2026, plus the warrant shares. Commodore Capital LP, Commodore Capital Master LP, and individuals Robert Egen Atkinson and Michael Kramarz share voting and dispositive power over the reported shares.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics, which is why the stake is reported on a Schedule 13G instead of a control‑oriented Schedule 13D.
Century Therapeutics, Inc. received a Schedule 13G filing showing a significant passive ownership position by TCG Crossover funds and Chen Yu in its common stock. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., through their respective general partners, each report beneficial ownership of 8,877,215 shares of common stock, representing 4.9% of the class. Chen Yu, as managing member of both general partners, reports aggregate beneficial ownership of 17,754,430 shares, or 9.9% of the common stock, based on 179,337,686 shares outstanding as of January 9, 2026.
The filing notes additional Pre-Funded Warrants and Common Stock Warrants that could be settled in more shares but are excluded because they are not exercisable within 60 days and are subject to a 9.99% Beneficial Ownership Limitation. The reporting parties certify the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.
Century Therapeutics, Inc. received a Schedule 13G reporting that Deep Track Capital and related entities beneficially own 13,486,400 shares of its common stock, representing 7.34% of the class. The filing aggregates positions held by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and individual reporting person David Kroin, all with shared voting and dispositive power over these shares.
The ownership calculation is based on 183,685,512 shares, including common stock outstanding and additional common stock issued, plus 4,347,826 shares underlying warrants that are subject to a 9.99% beneficial ownership limitation. The reporting persons state that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.
Century Therapeutics, Inc. filed a current report to notify investors that it has updated its corporate slide presentation. The revised investor presentation, dated January 12, 2026, is attached as Exhibit 99.1 and may be used by company representatives in meetings with investors from time to time.
The company states that the information in this report and the attached presentation is being furnished rather than filed under the securities laws, meaning it is not automatically incorporated into other securities filings unless specifically referenced.